跳至主要内容
临床试验/NCT00009789
NCT00009789已完成1 期

Accelerated Conformal Radiotherapy for Stage I Non-Small Cell Lung Cancer in Patients With Pulmonary Dysfunction: A Phase I Study

Alliance for Clinical Trials in Oncology40 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2000年12月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
39
试验地点
40
主要终点
Overall survival

研究概览

简要总结

RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: Phase I trial to study the effectiveness of specialized high-dose radiation therapy in treating patients who have stage I non-small cell lung cancer and lung dysfunction.

详细描述

OBJECTIVES:

  • Determine the maximum tolerated course of accelerated 3-dimensional conformal radiotherapy in patients with stage I non-small cell lung cancer with pulmonary dysfunction.
  • Determine the short-term and long-term toxicity of this regimen in these patients.
  • Determine local tumor control, failure-free survival, and overall survival in patients treated with this regimen.
  • Determine the effect of radiotherapy dose volume relationships and pre-treatment pulmonary function studies on the incidence of pulmonary toxicity in these patients.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.

Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Overall survival

时间窗: Up to 5 years

Failure-free survival

时间窗: Up to 5 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (40)

Loading locations...

相似试验

已完成
1 期
Radiation Therapy in Treating Patients With Liver MetastasesMetastatic Cancer
NCT00255814Radiation Therapy Oncology Group26
Unknown
1 期
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal CancerColorectal Cancer
NCT00392470Centre Hospitalier Universitaire Vaudois20
已完成
2 期
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for EpendymomaCentral Nervous System TumorBrain Tumor
NCT00027846Children's Oncology Group378
已完成
1 期
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance StatusLung Cancer
NCT00986297University of Texas Southwestern Medical Center60
终止
1 期
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCCSalivary Gland Squamous Cell CarcinomaStage II Salivary Gland CancerStage II Squamous Cell Carcinoma of the HypopharynxStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage II Squamous Cell Carcinoma of the OropharynxStage II Verrucous Carcinoma of the Oral CavityStage III Salivary Gland CancerStage III Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the OropharynxStage III Verrucous Carcinoma of the Oral CavityStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the OropharynxStage IV Verrucous Carcinoma of the Oral Cavity
NCT01283178Virginia Commonwealth University3
Radiation Therapy in Treating Patients With Stage I... | 临床试验